<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.3.1'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//www.biotechreality.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://www.biotechreality.com/2026/11/fda-rejected-ivonescimab-summit-therapeutics.html</loc>
  <lastmod>2026-11-16T02:47:00Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study</news:title>
   <news:publication_date>2026-11-16T02:46:55Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/11/cagrisema-redefine-9-novo-nordisk-obesityweek-2026.html</loc>
  <lastmod>2026-11-15T08:04:30Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026</news:title>
   <news:publication_date>2026-11-15T08:04:27Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/11/takeda-orzeyful-launch-narcolepsy-type-1-us.html</loc>
  <lastmod>2026-11-14T08:23:13Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Takeda ORZEYFUL Launch Brings First Orexin Agonist for Narcolepsy Type 1 to U.S. Patients</news:title>
   <news:publication_date>2026-11-14T08:23:08Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/11/cipher-pharmaceuticals-q3-2026-results.html</loc>
  <lastmod>2026-11-13T19:06:40Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Cipher Pharmaceuticals Q3 2026 Results: Epuris Sales Rise 15%, Natroba Gains 14% as Net Income Hits $10.9M</news:title>
   <news:publication_date>2026-11-13T19:06:25Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
